Uracil as a biomarker for spatial pyrimidine metabolism in the development of gingivobuccal oral squamous cell carcinoma.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
21 May 2024
Historique:
received: 26 12 2023
accepted: 16 05 2024
medline: 22 5 2024
pubmed: 22 5 2024
entrez: 21 5 2024
Statut: epublish

Résumé

No biomarker has yet been identified that allows accurate diagnosis and prognosis of oral cancers. In this study, we investigated the presence of key metabolites in oral cancer using proton nuclear magnetic resonance (NMR) spectroscopy to identify metabolic biomarkers of gingivobuccal oral squamous cell carcinoma (GB-OSCC). NMR spectroscopy revealed that uracil was expressed in 83.09% of tumor tissues and pyrimidine metabolism was active in GB-OSCC; these results correlated well with immunohistochemistry (IHC) and RNA sequencing data. Based on further gene and protein analyses, we proposed a pathway for the production of uracil in GB-OSCC tissues. Uridinetriphosphate (UTP) is hydrolyzed to uridine diphosphate (UDP) by CD39 in the tumor microenvironment (TME). We hypothesized that UDP enters the cell with the help of the UDP-specific P2Y6 receptor for further processing by ENTPD4/5 to produce uracil. As the ATP reserves diminish, the weakened immune cells in the TME utilize pyrimidine metabolism as fuel for antitumor activity, and the same mechanism is hijacked by the tumor cells to promote their survival. Correspondingly, the differential expression of ENTPD4 and ENTPD5 in immune and tumor cells, respectively, indicatedtheir involvement in disease progression. Furthermore, higher uracil levels were detected in patients with lymph node metastasis, indicating that metastatic potential is increased in the presence of uracil. The presence of uracil and/or expression patterns of intermediate molecules in purine and pyrimidine pathways, such asCD39, CD73, and P2Y6 receptors together with ENTPD4 and ENTPD5, hold promise as biomarker(s) for oral cancer diagnosis and prognosis.

Identifiants

pubmed: 38773214
doi: 10.1038/s41598-024-62434-z
pii: 10.1038/s41598-024-62434-z
doi:

Substances chimiques

pyrimidine 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

11609

Subventions

Organisme : Department of Biotechnology, Ministry of Science and Technology, India
ID : No./BT/Med-II/NIBMG/SyMeC/2014/Vol II).
Organisme : Department of Biotechnology, Ministry of Science and Technology, India
ID : No./BT/Med-II/NIBMG/SyMeC/2014/Vol II).

Informations de copyright

© 2024. The Author(s).

Références

Mathur, P. et al. Cancer trends and burden in India: Authors’ response. Lancet Oncol. 9, e664. https://doi.org/10.1016/S1470-2045(18)30857-X (2018).
doi: 10.1016/S1470-2045(18)30857-X
Mandlik, D. S. et al. Squamous cell carcinoma of gingivobuccal complex: Literature, evidences and practice. J. Head Neck Physicians Surg. 6, 18–28. https://doi.org/10.4103/jhnps.jhnps_19_18 (2018).
doi: 10.4103/jhnps.jhnps_19_18
Walvekar, R. R. et al. Squamous cell carcinoma of the gingivobuccal complex: Predictors of locoregional failure in stage III-IV cancers. Oral. Oncol. 45, 135–140. https://doi.org/10.1016/j.oraloncology.2008.04.007 (2009).
doi: 10.1016/j.oraloncology.2008.04.007 pubmed: 18621571
Singhania, V., Jayade, B. V., Anehosur, V., Gopalkrishnan, K. & Kumar, N. Carcinoma of buccal mucosa: A site specific clinical audit. Indian J. Cancer 52, 605–610. https://doi.org/10.4103/0019-509X.178383 (2015).
doi: 10.4103/0019-509X.178383 pubmed: 26960492
Manjula, B. V., Augustine, S. & Selvam, S. Mohan AM (2015) Prognostic and predictive factors in gingivo buccal complex squamous cell carcinoma: Role of tumor budding and pattern of invasion. Indian J. Otolaryngol. Head Neck Surg. 67, 98–104. https://doi.org/10.1007/s12070-014-0787-2 (2015).
doi: 10.1007/s12070-014-0787-2 pubmed: 25621262
Yegutkin, G. G. & Boison, D. ATP and adenosine metabolism in cancer: Exploitation for therapeutic gain. Pharmacol. Rev. 74, 797–822. https://doi.org/10.1124/pharmrev.121.000528 (2022).
doi: 10.1124/pharmrev.121.000528 pubmed: 35738682
Wu, H. L. et al. Targeting nucleotide metabolism: A promising approach to enhance cancer immunotherapy. J. Hematol. Oncol. 15, 45. https://doi.org/10.1186/s13045-022-01263-x (2022).
doi: 10.1186/s13045-022-01263-x pubmed: 35477416 pmcid: 9044757
Bonora, M. et al. ATP synthesis and storage. Purinergic Signal 8, 343–357. https://doi.org/10.1007/s11302-012-9305-8 (2012).
doi: 10.1007/s11302-012-9305-8 pubmed: 22528680 pmcid: 3360099
Antonioli, L., Pacher, P., Vizi, E. S. & Haskó, G. CD39 and CD73 in immunity and inflammation. Trends Mol. Med. 19, 355–367. https://doi.org/10.1016/j.molmed.2013.03.005 (2013).
doi: 10.1016/j.molmed.2013.03.005 pubmed: 23601906 pmcid: 3674206
Kepp, O. et al. ATP and cancer immunosurveillance. EMBO J40, e108130. https://doi.org/10.15252/embj.2021108130 (2021).
doi: 10.15252/embj.2021108130
Zhao, Y. et al. Identification of novel CD39 inhibitors based on virtual screening and enzymatic assays. J. Chem. Inf. Model 62, 5289–5304. https://doi.org/10.1021/acs.jcim.1c00590 (2022).
doi: 10.1021/acs.jcim.1c00590 pubmed: 34648290
Cui, H., Lan, Z., ZouKL, ZhaoYY. & Yu, G. T. STAT3 promotes differentiation of monocytes to MDSCs via CD39/CD73-adenosine signal pathway in oral squamous cell carcinoma. Cancer Immunol. Immunother. 72, 1315–1326. https://doi.org/10.1007/s00262-022-03336-9 (2023).
doi: 10.1007/s00262-022-03336-9 pubmed: 36436019
Bag, S. et al. Impact of spatial metabolomics on immune-microenvironment in oral cancer prognosis: A clinical report. Mol. Cell. Biochem. https://doi.org/10.1007/s11010-023-04713-3 (2023).
doi: 10.1007/s11010-023-04713-3 pubmed: 36966422
Robson, S. C., Sevigny, J. & Zimmermann, H. The E-NTPDase family of ectonucleotidases: Structure function relationships and pathophysiological significance. Purinergic Signal 2, 409–430. https://doi.org/10.1007/s11302-006-9003-5 (2006).
doi: 10.1007/s11302-006-9003-5 pubmed: 18404480 pmcid: 2254478
Vipparthi, K. et al. Two novel cell culture models of buccal mucosal oral cancer from patients with no risk-habits of tobacco smoking or chewing. Oral Oncol 113, 105131. https://doi.org/10.1016/j.oraloncology.2020.105131 (2020).
doi: 10.1016/j.oraloncology.2020.105131 pubmed: 33387705
Yuan, M., Breitkopf, S. B., Yang, X. & Asara, J. M. A positive/negative ion-switching, targeted mass spectrometry-based metabolomics platform for bodily fluids, cells, and fresh and fixed tissue. Nat. Protoc. 7, 872–881. https://doi.org/10.1038/nprot.2012.024 (2012).
doi: 10.1038/nprot.2012.024 pubmed: 22498707 pmcid: 3685491
Hutchins, G. & Grabsch, H. I. How to make tissue microarrays. Diagn. Histopathol. 24, 127–135 (2018).
doi: 10.1016/j.mpdhp.2018.02.008
Hendry, S. et al. Assessing tumor-infiltrating lymphocytes in solid tumors: A practical review for pathologists and proposal for a standardized method from the international immuno-oncology biomarkers working group: Part 2: TILs in melanoma, gastrointestinal tract carcinomas, non-small cell lung carcinoma and mesothelioma, endometrial and ovarian carcinomas, squamous cell carcinoma of the head and neck, genitourinary carcinomas, and primary brain tumors. Adv. Anat. Pathol. 24, 311–335. https://doi.org/10.1097/PAP.0000000000000161 (2017).
doi: 10.1097/PAP.0000000000000161 pubmed: 28777143 pmcid: 5638696
Yuan, J. & Kroemer, G. Alternative cell death mechanisms in development and beyond. Genes Dev 24, 2592–2602. https://doi.org/10.1101/gad.1984410 (2010).
doi: 10.1101/gad.1984410 pubmed: 21123646 pmcid: 2994033
Stoll, G. et al. Pro-necrotic molecules impact local immunosurveillance in human breast cancer. Oncoimmunology 6, e1299302. https://doi.org/10.1080/2162402X.2017.1299302 (2017).
doi: 10.1080/2162402X.2017.1299302 pubmed: 28507808 pmcid: 5414877
von Kügelgen, I. & Harden, T. K. Molecular pharmacology, physiology, and structure of the P2Y receptors. Adv. Pharmacol. 61, 373–415. https://doi.org/10.1016/B978-0-12-385526-8.00012-6 (2011).
doi: 10.1016/B978-0-12-385526-8.00012-6
Zimmermann, A. et al. Mapping the binding sites of UDP and prostaglandin E2 glyceryl ester in the nucleotide receptor P2Y6. ChemMedChem 17, e202100683. https://doi.org/10.1002/cmdc.202100683 (2022).
doi: 10.1002/cmdc.202100683 pubmed: 35034430 pmcid: 9305961
Irannejad, R. & von Zastrow, M. GPCR signaling along the endocytic pathway. CurrOpin. Cell. Biol. 27, 109–116. https://doi.org/10.1016/j.ceb.2013.10.003 (2014).
doi: 10.1016/j.ceb.2013.10.003
Villela, A. D. et al. Biochemical characterization of uracil phosphoribosyltransferase from Mycobacterium tuberculosis. PLoS One 8, e56445. https://doi.org/10.1371/journal.pone.0056445 (2013).
doi: 10.1371/journal.pone.0056445 pubmed: 23424660 pmcid: 3570474
Nagana Gowda, G. A. & Raftery, D. NMR-based metabolomics. Adv. Exp. Med. Biol. 1280, 19–37. https://doi.org/10.1007/978-3-030-51652-9_2 (2021).
doi: 10.1007/978-3-030-51652-9_2 pubmed: 33791972
Hu, R., Li, T., Yang, Y. & TianY, Z. L. NMR-based metabolomics in cancer research. Adv. Exp. Med. Biol. 1280, 201–218. https://doi.org/10.1007/978-3-030-51652-9_14 (2021).
doi: 10.1007/978-3-030-51652-9_14 pubmed: 33791984
Boguszewicz, Ł et al. NMR-based metabolomics in investigation of the radiation induced changes in blood serum of head and neck cancer patients and its correlation with the tissue volumes exposed to the particulate doses. Int. J. Mol. Sci. 22, 6310. https://doi.org/10.3390/ijms22126310 (2021).
doi: 10.3390/ijms22126310 pubmed: 34208417 pmcid: 8231285
Yatsuoka, W. et al. Time-course of salivary metabolomic profiles during radiation therapy for head and neck cancer. J. Clin. Med. 10, 2631. https://doi.org/10.3390/jcm10122631 (2021).
doi: 10.3390/jcm10122631 pubmed: 34203786 pmcid: 8232617
XiongY, S. Y., Feng, Y., Zhuo, S. & CuiB, Z. Z. Prognostic value of lipid metabolism-related genes in head and neck squamous cell carcinoma. ImmunInflamm. Dis. 9, 196–209. https://doi.org/10.1002/iid3.379 (2021).
doi: 10.1002/iid3.379
Wang, H. et al. Tissue metabolic profiling of human gastric cancer assessed by
doi: 10.1186/s12885-016-2356-4 pubmed: 27356757 pmcid: 4928316
de Sá, A. M. et al. Identification of possible salivary metabolic biomarkers and altered metabolic pathways in South American patients diagnosed with oral squamous cell carcinoma. Metabolites 11, 650. https://doi.org/10.3390/metabo11100650 (2021).
doi: 10.3390/metabo11100650
Li, J. et al. Necroptosis in head and neck squamous cellcarcinoma:characterization of clinicopathological relevance and in vitro cell model. Cell Death Dis. 11, 391. https://doi.org/10.1038/s41419-020-2538-5 (2020).
doi: 10.1038/s41419-020-2538-5 pubmed: 32444644 pmcid: 7244585
Zhang, T., Wang, Y., Inuzuka, H. & Wei, W. Necroptosis pathways in tumorigenesis. Semin. Cancer Biol. 86, 32–40. https://doi.org/10.1016/j.semcancer.2022.07.007 (2022).
doi: 10.1016/j.semcancer.2022.07.007 pubmed: 35908574 pmcid: 11010659
Vadlamani, V. M. K., Gunasinghe, K. K. J., Chee, X. W., Rahman, T. & Harper, M. T. Human soluble CD39 displays substrate inhibition in a substrate-specific manner. Sci. Rep. 13, 8958. https://doi.org/10.1038/s41598-023-36257-3 (2023).
doi: 10.1038/s41598-023-36257-3 pubmed: 37268726 pmcid: 10238538
Wilson, P. M., Fazzone, W., LaBonte, M. J., Lenz, H. J. & Ladner, R. D. Regulation of human dUTPase gene expression and p53-mediated transcriptional repression in response to oxaliplatin-induced DNA damage. Nucleic Acids Res. 37, 78–95. https://doi.org/10.1093/nar/gkn910 (2009).
doi: 10.1093/nar/gkn910 pubmed: 19015155
Olinski, R., Slupphaug, G., Foksinski, M. & Krokan, H. E. Genomic uracil and aberrant profile of demethylation intermediates in epigenetics and hematologic malignancies. Int. J. Mol. Sci. 22, 4212. https://doi.org/10.3390/ijms22084212 (2021).
doi: 10.3390/ijms22084212 pubmed: 33921666 pmcid: 8073381
Siddiqui, A. & Ceppi, P. A non-proliferative role of pyrimidine metabolism in cancer. Mol. Metab. 35, 100962. https://doi.org/10.1016/j.molmet.2020.02.005 (2020).
doi: 10.1016/j.molmet.2020.02.005 pubmed: 32244187 pmcid: 7096759
Ma, X. et al. Chemotherapy-induced uridine diphosphate release promotes breast cancer metastasis through P2Y6 activation. Oncotarget 7, 29036–29050. https://doi.org/10.18632/oncotarget.8664 (2016).
doi: 10.18632/oncotarget.8664 pubmed: 27074554 pmcid: 5045376
Gkotsos, G. et al. The role of sarcosine, uracil, and kynurenic acid metabolism in urine for diagnosis and progression monitoring of prostate cancer. Metabolites 7, 9. https://doi.org/10.3390/metabo7010009 (2017).
doi: 10.3390/metabo7010009 pubmed: 28241496 pmcid: 5372212
Qin, J. et al. The UDP/P2Y6 axis promotes lung metastasis of melanoma by remodeling the premetastatic niche. Cell. Mol. Immunol. 17, 1269–1271. https://doi.org/10.1038/s41423-020-0392-0 (2020).
doi: 10.1038/s41423-020-0392-0 pubmed: 32144377 pmcid: 7784845
Placet, M. et al. The G protein-coupled P2Y6 receptor promotes colorectal cancer tumorigenesis by inhibiting apoptosis. Biochim. Biophys. Acta Mol. Basis Dis. 1864, 1539–1551. https://doi.org/10.1016/j.bbadis.2018.02.008 (2018).
doi: 10.1016/j.bbadis.2018.02.008 pubmed: 29454075
Zhang, Z., Wu, H., ChenZ, L. G. & Liu, B. Circular RNA ATXN7 promotes the development of gastric cancer through sponging miR-4319 and regulating ENTPD4. Cancer Cell Int. 20, 25. https://doi.org/10.1186/s12935-020-1106-5 (2020).
doi: 10.1186/s12935-020-1106-5 pubmed: 31997941 pmcid: 6979400
Chen, X. et al. Knockdown of ENTPD5 inhibits tumor metastasis and growth via regulating the GRP78/p-eIF-2α/CHOP pathway in serous ovarian cancer. J. Ovarian Res. 15, 69. https://doi.org/10.1186/s13048-022-00996-0 (2022).
doi: 10.1186/s13048-022-00996-0 pubmed: 35668504 pmcid: 9171961
Biederbick, A., Kosan, C., Kunz, J. & Elsässer, H. P. First apyrase splice variants have different enzymatic properties. J. Biol. Chem. 275, 19018–19024. https://doi.org/10.1074/jbc.M001245200 (2000).
doi: 10.1074/jbc.M001245200 pubmed: 10858452
Vogiatzi, F. et al. Mutant p53 promotes tumor progression and metastasis by the endoplasmic reticulum UDPase ENTPD5. Proc. Natl. Acad. Sci. U.S.A 113, E8433–E8442. https://doi.org/10.1073/pnas.1612711114 (2016).
doi: 10.1073/pnas.1612711114 pubmed: 27956623 pmcid: 5206569

Auteurs

Soni Shaikh (S)

Tata Medical Center, 14 MAR (E-W), New Town, Rajarhat, Kolkata, WB, 700160, India.
Tata Consultancy Services (TCS), Kolkata, WB, India.

Sangramjit Basu (S)

Tata Translational Cancer Research Centre (TTCRC), 14 MAR (E-W), New Town, Rajarhat, Kolkata, WB, 700160, India.

Swarnendu Bag (S)

Tata Medical Center, 14 MAR (E-W), New Town, Rajarhat, Kolkata, WB, 700160, India.
CSIR-Institute of Genomics and Integrative Biology (IGIB), Mall Road, New Delhi, 110007, India.

Ankita Chatterjee (A)

National Institute of Biomedical Genomics, P.O.: N.S.S., Kalyani, WB, 741251, India.

Sourav Datta (S)

Narayana Superspeciality Hospital, 120, 1, Andul Rd, Shibpur, Howrah, WB, 711103, India.
Medica Superspecialty Hospital, 127, Eastern Metropolitan Bypass, Nitai Nagar, Mukundapur, Kolkata, WB, 700099, India.

Devmalya Banerjee (D)

Narayana Superspeciality Hospital, 120, 1, Andul Rd, Shibpur, Howrah, WB, 711103, India.

Kapila Manikantan (K)

Tata Medical Center, 14 MAR (E-W), New Town, Rajarhat, Kolkata, WB, 700160, India.

Indu Arun (I)

Tata Medical Center, 14 MAR (E-W), New Town, Rajarhat, Kolkata, WB, 700160, India.

Pattatheyil Arun (P)

Tata Medical Center, 14 MAR (E-W), New Town, Rajarhat, Kolkata, WB, 700160, India.

Nidhan K Biswas (NK)

National Institute of Biomedical Genomics, P.O.: N.S.S., Kalyani, WB, 741251, India.

Arindam Maitra (A)

National Institute of Biomedical Genomics, P.O.: N.S.S., Kalyani, WB, 741251, India.

Deepak Kumar Mishra (DK)

Tata Medical Center, 14 MAR (E-W), New Town, Rajarhat, Kolkata, WB, 700160, India.

Partha P Majumder (PP)

National Institute of Biomedical Genomics, P.O.: N.S.S., Kalyani, WB, 741251, India.
John C. Martin Centre for Liver Research and Innovations, Sitala East, IILDS, Hospital Road, Rajpur Sonarpur, Kolkata, WB, 700150, India.

Harsh Dhar (H)

Narayana Superspeciality Hospital, 120, 1, Andul Rd, Shibpur, Howrah, WB, 711103, India. harsh.dhar@medicasynergie.in.
Medica Superspecialty Hospital, 127, Eastern Metropolitan Bypass, Nitai Nagar, Mukundapur, Kolkata, WB, 700099, India. harsh.dhar@medicasynergie.in.

Geetashree Mukherjee (G)

Tata Medical Center, 14 MAR (E-W), New Town, Rajarhat, Kolkata, WB, 700160, India. geetashree.mukherjee@tmckolkata.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH